PRODUCTION

Industrial production of food products and medicines based on human milk lactoferrin is practically impossible due to the impossibility of obtaining human breast milk on a large scale. An effective solution was found using cow's milk lactoferrin (bLf), which, like human lactoferrin, has bactericidal properties. Despite the proven effectiveness and safety of bLf, isolated from cow's milk, its use in medical practice has not become widespread.

It is known that the set of amino acids of hLF and bLF coincide only by 67%. Differences in the primary structure of bLF and hLF determine the formation of different secondary and tertiary structures of these proteins, which can determine their functional features. Differences in the structure of receptors of various human organs and tissues to hLF and bLF have been found.

hLf in injectable drugs

The lactoferricins formed during the breakdown of bLf and hLf also differ in both their amino acid composition and biological activity. Thus, the implementation of the biological activity of bLf in vitro and in the human body can differ significantly from the effect of hLf, which, when manifesting its protective functions, interacts with other human bactericidal proteins.

Immunologists rightly believe that due to the xenogenicity of bLf in relation to hLf, its biological safety is limited, while hLf is acceptable as part of injectable drugs.

Lacto Therapeutics

The Lacto Therapeutics company is actively working with recombinant human lactoferrin. According to the data from the studies, both in terms of physicochemical parameters and biological activity, rhLf isolated from producers corresponded to the natural protein of hLf.

When creating gene constructs, no DNA sequences were used that could subsequently prove harmful to humans, therefore, no genetically modified elements were found in either the milk of producers or rhLf.